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clinical (bedside) and laboratory (bench). The clinician
always wants to know what the fungus is and how to
treatment the mycosis. Fungal pathogens are often stealthy
and difﬁcult to detect in infected patients during the early
stages of the diseases and this is when therapies would be
the most effective. Routine techniques commonly employed
in the detection of fungal diseases including microscopic
examination, culturing and serology are seriously hampered
by lengthy waits of times for results and low accuracy. The
clinician may want prophylaxis or to use empirical antifungal
treatment to see if it does/does not work. The problem is
that some of the patients do not respond to the antifungal
treatment, because the doctor lacked sufﬁcient evidence of
fungus infection to give the doctor conﬁdence to continue
treatment. Accurate and early diagnosis of fungal diseases
is critical for managing mycotic diseases. Our experience is
before starting antifungal treatment, we need to be sure
the tissue was invaded by a fungus. This is usually done by
direct microscopic examination (DME) of KOH preparations.
Good specimens are the key point that directly affects
the quality of microscopic evidence and culture. The most
important aspect is culturing samples on different media
with or without chloramphenicol and cycloheximide and
incubated at room temperature and 37ºC. PCR-based no-
culture methods are necessary in the cases of culture
negative, morphologic identiﬁcation not success, and, to
prove the species identiﬁed by routine. Early treatment
could save a patient’s life. We start treatment at the time
we have the proof of fungal infection, i.e., KOH positive.
Itraconazole, ﬂuconazole, terbinaﬁne, amphotericin B or its
liposome form, can be used alone or in combination based
on the fungal species involved and the site of infection.
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Scheme for diagnosis and treatment of invasive fungal infections.
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The diagnosis and treatment of HCV (Hepatitis C Virus) has
been changing drastically for the last 20 years. Therefore,
we feel the need to revise the guidelines maybe every 2 to
3 years to update the knowledge for clinical use.
The last publication on HCV guideline was 1992 by Dr. Geoff
McCaugh and and myself with 17 co-authors. However after
that, there is remarkable progress in understanding of the
pathogenesis and natural courses of HCV infection. For
example, the discovery of IL28b SNP revolutionized and
changed interferon treatment indications.
Recently, the SNP analysis chronicle HCV infection was
performed on large scale matters in Japanese patients,
and it was revealed several signiﬁcant SNPs were identiﬁed
to inﬂuence on the natural courses of the hepatitis virus
infection. Furthermore, the remarkable effort to develop
the innovative drugs for the treatment and cure of HCV
infection has been conducted for the last 10 years, and new
Protease Inhibitors will be on the market shortly. These new
drugs may change the paradigm of the treatment of HCV
infections totally, and we are now in vision even the total
cure of the diseases. Therefore, we are now in process to
revise APASL guidelines to be able to catch up the incredible
progress of the management on HCV infections.
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Personalized therapy based on current standard of care,
pegylated interferon-a (PegIFN) plus ribavirin (RBV), has
become the mainstay for treatment of chronic hepatitis C
virus (HCV).
Genotype-guided therapy, based on HCV genotype,
recommended a 48-week regimen of PegIFN plus weight-
based RBV (1000 1200mg/d) for HCV genotype 1 or 4
(HCV-1/4); and a 24-week regimen of PegIFN plus ﬁxed,
low dose of RBV (800 mg/d) for HCV-2/3 infection.
The sustained virological response (SVR, serum HCV RNA
<50 IU/ml throughout 6 months of post-treatment follow-up
period) rate is around 50% and 83% for HCV-1/4 patients and
HCV-2/3 patients, respectively in Caucasian; and 70 75% and
85 90% in Asian patients, respectively. The optimal regimens
for HCV-5 or 6 remain to be determined.
Recently, response-guided therapy, based on on-treatment
virological responses, has become the new era of care. A
shorter 24-week regimen for HCV-1 with lower baseline viral
loads and a rapid virological response (RVR, serum HCV RNA
<50 IU/ml at 4 weeks of treatment) and an abbreviated 16-
week regimen with weight-based, standard dose of RBV for
HCV-2/3 could provide equal efﬁcacy to genotype-guided
SOC. By contrast, treatment should be stopped for HCV-1
patients without an early virological response (EVR, serum
HCV RNA <50 IU/ml or a 2 logs decline of HCV RNA from
baseline after 12 weeks of therapy). Furthermore, EVR has
been suggested to be subdivided into RVR, complete EVR
(no RVR, but HCV RNA <50 IU/ml at week 12) and partial
EVR (HCV RNA >2 log drop in HCV RNA but still detectable at
week 12) to further improve the prediction of patients who
are likely to achieve an SVR and may allow for extending
treatment duration to 72 weeks, especially for those of slow
responders.
More recently, the development of direct antiviral agents
(DAA, formally named speciﬁcally targeted antiviral therapy
for HCV, STAT-C) is ongoing. DAA has increased the number
